Discover and read the best of Twitter Threads about #SABCS21
Most recents (3)
1) Welcome to our THIRD #accredited serialized #tweetorial from @onc_ce, your new (and only) home for the latest education from #experts on #cancer care. #Physicians #nurses #pharmacists #PAs and #NPs can all earn 0.5h CE/#CME by following this thread!
2) We continue to highlight the San Antonio Breast Cancer Symposium (#SABCS21), with more expert commentary for OUR #tweetorial followers! Our content authority is Hal Burstein MD (@drhburstein) from @DanaFarber Cancer Institute & @HarvardMed.
3) @Onc_ce and its companion website oncologytweetorials-ce.com are supported by educational grants from Astra Zeneca and Daiichi Sankyo and content is intended for #healthcare providers. Faculty disclosures are listed at oncologytweetorials-ce.com/disclosures/.
1/14 🆕 🚨Accelerated article on #breastcancer just out in @nature! #bcsm
We asked:
1️⃣ What drives response to #chemotherapy in #breast #cancer❓
2️⃣ Can we use #machinelearning to predict response to chemotherapy❓
Link: nature.com/articles/s4158…
A 🧵👇👇👇 @OncoAlert
We asked:
1️⃣ What drives response to #chemotherapy in #breast #cancer❓
2️⃣ Can we use #machinelearning to predict response to chemotherapy❓
Link: nature.com/articles/s4158…
A 🧵👇👇👇 @OncoAlert
2/14 We are unable to #predict #response to treatment in clinic…
✅Good response ➡️treatment very effective ➡️better survival
❌Poorer response ➡️treatment less effective ➡️worse survival
Being able to forecast response would be a landmark advance!
✅Good response ➡️treatment very effective ➡️better survival
❌Poorer response ➡️treatment less effective ➡️worse survival
Being able to forecast response would be a landmark advance!
3/14 We ran a study in women with #breastcancer @CUH_NHS+@CRUK_CI:
1️⃣who had a #cancer biopsy (which we analysed)
2️⃣received 18 weeks of chemo+/-targeted therapy
3️⃣had surgery (and we measured how much cancer remained)
We associated PRE-therapy profiles↔️POST-therapy response👇
1️⃣who had a #cancer biopsy (which we analysed)
2️⃣received 18 weeks of chemo+/-targeted therapy
3️⃣had surgery (and we measured how much cancer remained)
We associated PRE-therapy profiles↔️POST-therapy response👇
$OLMA San Antonio abstracts released tomorrow AM, so here’s a brief thread on expectations and how to contextualize the data #SABCS21
What does @OlemaOncology OP-1250 need to score in their Ph1 ER+/HER2 in mBC?
What does @OlemaOncology OP-1250 need to score in their Ph1 ER+/HER2 in mBC?
$OLMA Cross-trial of Ph1 SERDs have a wide range of ORRs ranging from 0 - 20%, but that alone doesn’t reflect how SOC has changed over time (ie. use of CDK4/6) or safety trade-offs
See $ARVN chart showing background use of Palbo and co. moving earlier in the treatment paradigm
See $ARVN chart showing background use of Palbo and co. moving earlier in the treatment paradigm
On $ARVN: 471 has been cited by sell-side/mgmt as OP-1250 benchmark
Yee wrongly notes a 21% ORR (+no DoR) - should be 7%; ARVN mgmt has told investors that both uPRs had new lesions before confirmation = SD
So a $1B u/f $PFE deal (up to $2.4B) for 7% ORR and clean safety
Yee wrongly notes a 21% ORR (+no DoR) - should be 7%; ARVN mgmt has told investors that both uPRs had new lesions before confirmation = SD
So a $1B u/f $PFE deal (up to $2.4B) for 7% ORR and clean safety
